{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T08:54:50Z","timestamp":1771923290013,"version":"3.50.1"},"reference-count":15,"publisher":"Centers for Disease Control and Prevention (CDC)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Emerg. Infect. Dis."],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.3201\/eid3004.231060","type":"journal-article","created":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T16:03:36Z","timestamp":1711123416000},"source":"Crossref","is-referenced-by-count":2,"title":["Effects of Shock and Vibration on Product Quality during Last-Mile Transportation of Ebola Vaccine under Refrigerated Conditions1"],"prefix":"10.3201","volume":"30","author":[{"given":"Linda","family":"Bus-Jacobs","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rute","family":"Lau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marjolein","family":"Soethoudt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Gebbia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edwin","family":"Janssens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tjeerd","family":"Hermans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1822","reference":[{"key":"key-10.3201\/eid3004.231060-202402281031-R1","unstructured":"Centers for Disease Control and Prevention. History of Ebola virus disease (EVD) outbreaks. 2022 [cited 2023 Jul 7]. https:\/\/www.cdc.gov\/vhf\/ebola\/history\/chronology.html"},{"key":"key-10.3201\/eid3004.231060-202402281031-R2","unstructured":"European Medicines Agency. Zabdeno. 2020 Jul [cited 2023 Mar 3]. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/zabdeno"},{"key":"key-10.3201\/eid3004.231060-202402281031-R3","unstructured":"European Medicines Agency. Mvabea. 2020 Nov [cited 2023 Mar 3]. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/mvabea"},{"key":"key-10.3201\/eid3004.231060-202402281031-R4","unstructured":"World Health Organization. List of prequalified vaccines [cited 2023 May 16]. https:\/\/extranet.who.int\/pqweb\/vaccines\/list-prequalified-vaccines"},{"key":"key-10.3201\/eid3004.231060-202402281031-R5","doi-asserted-by":"publisher","first-page":"e1003813","DOI":"10.1371\/journal.pmed.1003813","article-title":"Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa.","volume":"18","author":"Barry","year":"2021","journal-title":"PLoS Med"},{"key":"key-10.3201\/eid3004.231060-202402281031-R6","doi-asserted-by":"publisher","first-page":"e1003865","DOI":"10.1371\/journal.pmed.1003865","article-title":"Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial.","volume":"19","author":"Anywaine","year":"2022","journal-title":"PLoS Med"},{"key":"key-10.3201\/eid3004.231060-202402281031-R7","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/S1473-3099(21)00125-0","article-title":"Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial.","volume":"22","author":"Ishola","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"key-10.3201\/eid3004.231060-202402281031-R8","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/S1473-3099(21)00128-6","article-title":"Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial.","volume":"22","author":"Afolabi","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"key-10.3201\/eid3004.231060-202402281031-R9","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1056\/NEJMoa2200072","article-title":"Randomized trial of vaccines for Zaire Ebola virus disease.","volume":"387","author":"Kieh","year":"2022","journal-title":"N Engl J Med"},{"key":"key-10.3201\/eid3004.231060-202402281031-R10","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.ejpb.2018.06.001","article-title":"Stability and suitability for storage and distribution of Ad26.ZEBOV\/MVA-BN\u00ae-Filo heterologous prime-boost Ebola vaccine.","volume":"129","author":"Capelle","year":"2018","journal-title":"Eur J Pharm Biopharm"},{"key":"key-10.3201\/eid3004.231060-202402281031-R11","first-page":"11","article-title":"Forced degradation studies: an essential tool for the formulation development of vaccines.","volume":"3","author":"Hasija","year":"2013","journal-title":"Vaccine (Auckl)"},{"key":"key-10.3201\/eid3004.231060-202402281031-R12","unstructured":"European Medicines Agency. ICH Q6B specifications: test procedures and acceptance criteria for biotechnological\/biological products\u2014scientific guideline [cited 2023 May 16]. https:\/\/www.ema.europa.eu\/en\/ich-q6b-specifications-test-procedures-acceptance-criteria-biotechnological-biological-products"},{"key":"key-10.3201\/eid3004.231060-202402281031-R13","unstructured":"European Directorate for the Quality of Medicines & Healthcare. European pharmacopoeia [cited 2023 May 16]. https:\/\/www.edqm.eu\/en\/d\/99080"},{"key":"key-10.3201\/eid3004.231060-202402281031-R14","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/s41541-022-00470-4","article-title":"Development of functionally relevant potency assays for monovalent and multivalent vaccines delivered by evolving technologies.","volume":"7","author":"Sanyal","year":"2022","journal-title":"NPJ Vaccines"},{"key":"key-10.3201\/eid3004.231060-202402281031-R15","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1016\/j.vaccine.2020.02.002","article-title":"Examination of the effect of agitation on the potency of the Ebola Zaire vaccine rVSV\u0394G-ZEBOV-GP.","volume":"38","author":"Davis","year":"2020","journal-title":"Vaccine"}],"container-title":["Emerging Infectious Diseases"],"original-title":[],"link":[{"URL":"https:\/\/wwwnc.cdc.gov\/eid\/article\/30\/4\/23-1060_article","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T18:37:36Z","timestamp":1732905456000},"score":1,"resource":{"primary":{"URL":"https:\/\/wwwnc.cdc.gov\/eid\/article\/30\/4\/23-1060_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"URL":"https:\/\/doi.org\/10.3201\/eid3004.231060","relation":{},"ISSN":["1080-6040","1080-6059"],"issn-type":[{"value":"1080-6040","type":"print"},{"value":"1080-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4]]}}}